AstraZeneca's Imfinzi regimen showed improved survival in muscle-invasive bladder cancer
AstraZeneca's Imfinzi-based regimen significantly reduced the risk of disease progression, recurrence, or death in muscle-invasive bladder cancer, according to the Phase III NIAGARA trial.
A new treatment regimen combining AstraZeneca's Imfinzi (durvalumab) with chemotherapy has demonstrated significant results in treating muscle-invasive bladder cancer (MIBC).
The Phase III NIAGARA trial found that the Imfinzi-based regimen reduced the risk of disease progression, recurrence, not undergoing surgery, or death by 32% compared to neoadjuvant chemotherapy alone. Overall survival also showed a statistically significant improvement, with a 25% reduction in the risk of death.
According to the study results, 82.2% of patients treated with the Imfinzi regimen were alive at two years, compared to 75.2% in the comparator group. This marks the first immunotherapy regimen to show a statistically significant improvement in overall survival for patients with MIBC.
The findings were presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona and simultaneously published in The New England Journal of Medicine. The Imfinzi treatment represents a significant advancement in care for a disease where historically, half of patients experienced recurrence.